---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-015355"
form_type: "8-K"
ticker: "PCSA"
cik: "0001533743"
company_name: "Processa Pharmaceuticals, Inc."
filed_at: "2025-06-17T23:59:59+00:00"
generated_at: "2026-05-19T04:34:04.206843+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Processa grants Intact exclusive option to license PCS12852 for up to $452.5M milestones plus royalties

## Summary
- Near-term payments: $2.5M option exercise fee plus 3.5% equity stake in Intact upon closing.
- Up to $20M in development/regulatory milestones and over $432.5M in commercial milestones on net sales.
- Double-digit royalty on worldwide net sales (ex-South Korea); Processa must share 60% of cash payments with licensor Yuhan.
- PCS12852 is a Phase 2-ready 5-HT4 agonist for diabetic gastroparesis with positive Phase 2a safety/efficacy data.
- Definitive license agreement subject to 120-day diligence, extension for $30K, and Yuhan amendment.

## SEC filing metadata
- accession: 0001641172-25-015355
- form_type: 8-K
- ticker: PCSA
- cik: 0001533743
- company_name: Processa Pharmaceuticals, Inc.
- filed_at: 2025-06-17T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1533743/000164117225015355/0001641172-25-015355-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1533743/000164117225015355/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-015355
- JSON: https://secwatch.observer/filing/0001641172-25-015355.json
- Plain text: https://secwatch.observer/filing/0001641172-25-015355.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.